RxDoctor Payments Data

David Longcope, MD

Colon & Rectal Surgery · Denver, CONPI 1972522688

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $380,108 of the $425,381 with a category attached, or 89.4%. Medical Device Business Services, Inc. accounts for 76.7% of it on its own, with 16 other manufacturers making up the rest. Among colon & rectal surgery clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$425,381in general payments, 2019–2025

Across 345 payments — averaging $1232.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medical Device Business Services, Inc.$326K
  • Johnson & Johnson$74K
  • Ethicon Endo-surgery Inc.$24K
  • Braintree Laboratories, Inc.$185
  • Davol Inc.$157
  • Medtronic$101
  • plus $295 from 11 others

What the payments were for

  • Consulting fees$380,10889%
  • Travel & lodging$37,8929%
  • Food & beverage$7,1962%
  • Gifts$1850%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$425,381 in reported general payments places this provider in the 95th percentile of 24 colon & rectal surgery providers in Colorado.

See all colon & rectal surgery providers in Colorado

Medicare billing

Part B allowed, 2024
$94,030
Medicare patients
175
Services billed
394

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SutabSod Sulf/Pot Chloride/Mag Sulf22$3,566
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl28$361
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav26$211
Oxycodone Hcl33$182
Neomycin Sulfate19$121
Metronidazole23$74

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Braintree Laboratories, Inc.Sutab$185$3,56622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 24 colon & rectal surgery providers in Colorado.

Other colon & rectal surgery in Denver

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →